Member Info for EmeraldCarrots

In case anyone missed this:-

Shares Investor Webinar - 03 September 2024 (tomorrow).

https://www.sharesmagazine.co.uk/events/event/shares-investor-webinar-030924

Day of FDA clearance in the USA for the Genedrive® MT-RNR1 ID Kit. Assuming it gets clearance, and there is no reason why not, the sp will spike up. Trick will be to sell at the top. Usually that is 10:30 ish am. The FDA have said the machine has no equivalent...... it is unique.

Another reason why the sp here is silly low.

All IMHO.

Roger65.

Over 100m shares have been ussued since then. You would need to work out what the sp waoul have been diluted by the new share amount I think.

He probably thought all the placing shares had been sorted. The sp did pause around that level for a while before falling again down to where we are....... 2.25p.

1,000,000 x 3.1p = £31,000.00

1,000,000 x 2.2p = £22,000.00

=========================

A loss of £9,000.00, 29%. Ouch.

He probably thought all the placing shares had been sorted. The sp did pause around that level for a while before falling again down to where we are....... 2.25p.

1,000,000 x 3.1p = £31,000,000

1,000,000 x 2.2p = £22,000,000

=========================

A loss of £9,000.00, 29%. Ouch.

I suggest you don't until you can see evidence. Lies on the LSE board are quite common. LSE do not seem to care.

That NICE gave months before to Genedrive (and so the market). The market would NOT have expected the guidance to suddenly change to more favour Genedrive. The sp drop is most likely an overhancg being cleared, Once cleared the sp might take off. Seeing machines had the same a few years back and the sp more than doubled in weeks.

Draft guidance:-

https://www.nice.org.uk/guidance/dg59/documents/514-2

Draft guidance:-

"Laboratory-based testing

1.2 Use laboratory-based testing for CYP2C19 genotype testing.

Point-of-care testing

1.3 Use the Genedrive CYP2C19 ID Kit point-of-care test for CYP2C19

genotype testing when laboratory-based testing is not available.

1.4 Use the Genomadix Cube point-of-care test when laboratory-based

testing and the Genedrive CYP2C19 ID Kit point-of-care test are not

available"

All IMHO.

Evidence? Please advise where we find it?

A share, that being a 100% premium to the current share price (2.3p)................................

Share holders turn it down?

They increase to say 5.5p, final offer.

Then what? I would sell at the 4.6, let alone the 5.5p.

Bid to take over GDR is very, very likely it seems to me.

All IMHO.

So has the sp hit the floor? Only the big seller knows that. I sold a load @ 4.6p a few weeks back so quite how they have not sold out by now is a mystery. Massive mistake not selling when the sp was North of 4p???????? Or 3.5p???????? Or 3p??!!!!

The sp IMHO is crazy low. A bid could come in now offereing shareholders a 300% increase on todays price. So 3 x 2.3p = 6.9p a share. A 3 fold increase sounds good, does it not? How ridiculous.

All IMHO.

So has the sp hit the floor? Only the big seller knows that. I sold a load @ 4.6p a few weeks back so quite how they have not sold out by now is a mystery. Massive mistake not selling when the sp was North of 4p???????? Or 3.5p???????? Or 30??!!!!

All IMHO.

Evidence?

First 2 trades shown today..... 16:19?? Not today then.

6th & 7th trades timed 08:16, but the 4th & 5th were @ 08:30.......

In case anyone missed this:-

Shares Investor Webinar - 03 September 2024 (tomorrow).

https://www.sharesmagazine.co.uk/events/event/shares-investor-webinar-030924

Clearance. I can't see any way they won't get it, but it won't be next week. Some months. The Genedrive® MT-RNR1 ID Kit.

All IMHO. Patience is needed to top 8p a share. 3p a share is a different matter......

https://www.lse.co.uk/rns/GDR/breakthrough-device-designation-from-the-us-fda-2zclfstav7guqaq.html

You test weeks/months later in a person to find out the current state of their cancer? CtDna I hear you say. It has quite a lot of information, true. But a real live cancer tumour cell floating around in the blood (caught by Angle's Parsortix machine) is the only thing that should have all the information. Hello Illumina............. 50p a share? Maybe hello Astra...... Maybe hello bid war……….. maybe hello 90p a share?

End Of.

This article says that CtDna analysis is sometimes not sensitive enough. "If that happens, he explained, FDA recommends that the patient get a tissue biopsy to check for genetic changes.". Think circulating tumour cells (CTC's), as often there is no known tissue to test. CTC's are as close as you are going to get to an actual tissue sample IMHO. That is why Angle are sitting on a gold mine.

https://www.cancer.gov/news-events/cancer-currents-blog/2020/fda-guardant-360-foundation-one-cancer-liquid-biopsy

All IMHO.

You test weeks/months later in a person to find out the current state of their cancer? CtDna I hear you say. It has quite a lot of information, true. But a real live cancer tumour cell floating around in the blood (caught by Angle's Parsortix machine) is the only thing that should have all the information. Hello Illumina............. 50p a share? Maybe hello Astra...... Maybe hello bid war……….. maybe hello 90p a share?

End Of.

All IMHO.

The one that is used to test babies if they are suitable for the normal antibiotic treatment or not is selling and there is no real competition, so sales are likely to snowball all round the World. The application for American FDA clearance is in so expect the sp beyond 10p a share the day clearance is announced. I understand this is being fast tracked as there is no comparable device in existence.

The one that is used to test if stroke patients are suitable for clopidogrel treatment or not was only cleared by NICE 4 WEEKS ago. No doubt GDR will apply for FDA approval in the USA for this machine too.

All IMHO.

GordonGecko123.

If there is a profit warning that you have been harping on about for months, then you will have been right.

Your opinion is based on guesswork of course. A third of the year left for Angle to land a few major deals. No significant RNS's since the Astrazeneca one on 3rd May. In view of the flow of positive RNS's before that date and the fact we are nearly 4 months on it seems to me the odds are a positive RNS is not far away. Additional contracts with Eisai and Astrazeneca are most likely as they are already customers. It would be nice to see other massive Plc's on board like for instance Roche, Johnson & Johnson, Pfizer etc... Astrazeneca are of similar size to these no doubt they will be interested in why Astrazeneca are now placing orders with Angle. Also, why Eisai are too. I’m sure the World cancer drug trial industry would have noted that both Astrazeneca and Eisai Inc have contracted Angle to help them find out if they can use the live circulating tumour cells (CTC’s) Angles Parsortix machine can catch to further cancer knowledge and research. In the future catching and testing CTC’s from a standard blood sample may be used to decide the best cancer treatment to use.

The last big positive news RNS:-

https://www.lse.co.uk/rns/AGL/new-commercial-agreement-with-large-pharma-gvzk9wgh1la0ljx.html

I find your posts hilarious "with all the duty of care of a child left alone in a sweet shop". LOL!!!!!!!!!

"displaying a self-belief bordering on the messianic" LOL! LOL! LOL!

keep posting mate. Cherrs me up no end!

In case anyone missed this:-

Found it:-

https://www.sharesmagazine.co.uk/events/event/shares-investor-webinar-030924